PluS Nanoparticles Loaded with Sorafenib: Synthetic Approach and Their Effects on Endothelial Cells

Silica nanostructures are widely investigated for theranostic applications, since relatively mild and easy synthetic methods allow the fabrication of multi-compartment nanoparticles (NPs) and to finely modulate their properties. Here, we report the optimization of a synthetic strategy leading to brightly fluorescent silica NPs with a high loading ability – up to 45 molecules per NP – of Sorafenib, a small molecule acting as antiangiogenic drug. We demonstrate that these NPs can efficiently release the drug and they are able to inhibit endothelial cell proliferation, migration and network formation. Their lyophilization can endow them with long shelf stability while, once in solution, they show a much slower release compared to analogous micellar systems. Interestingly, Sorafenib released from PluS NPs completely prevented endothelial cell responses and post-receptor MAPK signaling ignited by VEGF, one of the major player of tumor angiogenesis. Our results indicate that these theranostic systems represent a promising structure for anti-cancer applications since NPs alone have no cytotoxic effect on cultured endothelial cells, a cell type to which drugs and exogenous material are always in contact once delivered